Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (18444)	4/1/1998 3:03:00 PM
From: Flagrante Delictu	Read Replies (2) \| Respond to of 32384

Henry, Upon a new reading of this release, I'm more unhappy than on the first reading. The investigator didn't go out of his way to provide any confidence level. He " characterized DAB389 il-2 as POTENTIALLY having clinically significant anti-tumor effect, even in patients with advanced CTCL who have received multiple prior therapies." " The trial was designed to assess the safety & efficacy of tratment with DANB389IL-2 at 2 dose levels in the target patient population." Are we to assume these were the agreed upon critical end points? "Preliminary statistical analysis of the trial results indicate that the TRUE response rate, based on a 95% confidence interval, lies BETWEEN 18 & 41%." They don't know? The only reliable statistic in my opinion was that"37% of the patients withdrew from the trial because of adverse events." While I have no background in this area, this release seems laughable. The only statistically significant numbers relate to responders. These may be secondary considerations. There is no statement that the primary endpoints were met with statistical significanse. More dropped out than had partial responses. Yuck!